Machine Learning Classifier for Predicting Immune Checkpoint Blockade Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to accurately predict which cancer patients will respond to immune checkpoint blockade (ICB) therapy across different cancer types, as no individual biological factor can optimally identify responsive patients.
Innovation Solution
A machine learning classifier is trained using a cohort of subjects with diverse cancer types, incorporating features like blood albumin, hemoglobin, and tumor mutation burden, and applying a random forest technique to predict responsiveness to ICB therapy, with hyperparameter optimization for accuracy and sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If a single biological factor is used to predict ICB responsiveness, then the prediction method is simple, but the prediction accuracy is insufficient
Solution Approach 1:
The patent combines multiple biological factors (tumor mutation burden, immune cell infiltration levels, gene expression profiles, and clinical parameters) into a single integrated machine learning model. This merging of multiple prediction features resolves the contradiction by achieving high prediction accuracy through comprehensive analysis while maintaining reasonable system complexity through automated computational processing.
Solution Approach 2:
The patent creates a composite predictive model that integrates heterogeneous data types including genomic data, transcriptomic data, and clinical data. This composite approach mirrors the principle of composite materials, where combining different components creates a system with superior properties compared to individual components alone, thereby achieving high prediction accuracy without excessive complexity.
2Measurement precision
If multiple biological factors are integrated to improve prediction accuracy, then the prediction precision increases, but the system complexity increases
Solution Approach 1:
The patent replaces complex manual analysis methods with automated machine learning algorithms. The random forest classifier and other computational models automatically process multiple biological factors, performing hyperparameter optimization and feature selection without requiring manual intervention. This substitution of computational automation for manual processes resolves the contradiction by managing system complexity through algorithmic efficiency while maintaining high prediction accuracy.
Solution Approach 2:
The patent dynamically adjusts model parameters including hyperparameter optimization, feature weighting, and threshold selection based on the specific cancer type and patient cohort. This parameter adaptability allows the system to optimize prediction accuracy for different scenarios without requiring fundamentally different system architectures, thereby managing complexity while maintaining high precision across diverse applications.
3Measurement precision
If cancer-type specific models are developed, then the prediction accuracy for each cancer type improves, but the overall system complexity increases
Solution Approach 1:
The patent divides the prediction system into cancer-type specific models, each trained on data from a particular cancer type. This segmentation allows each model to capture cancer-specific biological patterns and characteristics, achieving high prediction accuracy for each cancer type. The modular architecture of separate models actually reduces overall complexity compared to a single monolithic model, as each segment can be independently optimized and validated.
Solution Approach 2:
The patent develops a universal machine learning framework that can be applied across multiple cancer types. The same technical approach (random forest classifier with hyperparameter optimization) serves multiple cancer types, providing a multi-functional solution. This universality reduces complexity by using a consistent methodology across different applications rather than developing entirely separate systems for each cancer type.
Data Source
AI summary
The present disclosure relates generally to methods, devices, and systems for accurately predicting the efficacy of immune checkpoint blockade therapy across multiple cancer types.